Brokers Set Expectations for FDMT FY2025 Earnings

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings per share estimate for 4D Molecular Therapeutics from ($3.40) to ($3.60), indicating concerns about the company's financial performance.
• The current consensus estimate for 4D Molecular Therapeutics' full-year earnings stands at ($2.84) per share, reflecting a widespread bearish outlook among analysts.
• 4D Molecular Therapeutics shares recently traded at $7.19, with a market cap of $335.77 million, and have seen a stark price variation within the past year, having a low of $2.23 and a high of $17.41.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for 4D Molecular Therapeutics in a research report issued on Wednesday, August 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of ($3.60) per share for the year, down from their previous estimate of ($3.40). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for 4D Molecular Therapeutics' FY2026 earnings at ($2.87) EPS.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group cut their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Roth Capital cut their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Barclays cut their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Thursday, August 14th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $30.40.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock traded up $0.28 during midday trading on Friday, reaching $6.85. The company had a trading volume of 635,164 shares, compared to its average volume of 885,082. The stock has a fifty day moving average price of $4.77 and a 200 day moving average price of $4.16. The firm has a market cap of $319.91 million, a PE ratio of -1.94 and a beta of 2.83. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $17.41.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its position in shares of 4D Molecular Therapeutics by 1,607.1% during the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after purchasing an additional 1,337,497 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth approximately $532,000. Two Sigma Investments LP raised its position in shares of 4D Molecular Therapeutics by 196.3% during the fourth quarter. Two Sigma Investments LP now owns 313,993 shares of the company's stock worth $1,749,000 after purchasing an additional 208,021 shares during the period. Harbor Capital Advisors Inc. acquired a new position in shares of 4D Molecular Therapeutics during the first quarter worth approximately $99,000. Finally, Wells Fargo & Company MN raised its position in shares of 4D Molecular Therapeutics by 40.6% during the fourth quarter. Wells Fargo & Company MN now owns 25,852 shares of the company's stock worth $144,000 after purchasing an additional 7,463 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.